CorMedix Inc.

Informe acción NasdaqGM:CRMD

Capitalización de mercado: US$688.7m

CorMedix Dirección

Dirección controles de criterios 3/4

El CEO de CorMedix es Joe Todisco , nombrado en May 2022, tiene una permanencia de 2.5 años. compensación anual total es $2.46M, compuesta por 25.1% salario y 74.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.3% de las acciones de la empresa, por valor de $2.09M. La antigüedad media del equipo directivo y de la junta directiva es de 2.5 años y 2.7 años, respectivamente.

Información clave

Joe Todisco

Chief Executive Officer (CEO)

US$2.5m

Compensación total

Porcentaje del salario del CEO25.1%
Permanencia del CEO2.5yrs
Participación del CEO0.3%
Permanencia media de la dirección2.5yrs
Promedio de permanencia en la Junta Directiva2.7yrs

Actualizaciones recientes de la dirección

Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Nov 14
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Recent updates

Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Nov 14
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

Nov 04
Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

CorMedix 2.0: New Leadership, New Approval, New Focus

Oct 28

CorMedix: Delayed Approval, Low Cash, Good Prospects

Oct 19

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Sep 30
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

Apr 06
We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Nov 02
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 31
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

Feb 25
CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%

Aug 08

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 16
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Mar 01
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Sep 09
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix Inc.'s (NASDAQ:CRMD) Intrinsic Value Is Potentially 58% Above Its Share Price

Feb 11
CorMedix Inc.'s (NASDAQ:CRMD) Intrinsic Value Is Potentially 58% Above Its Share Price

We're Hopeful That CorMedix (NYSEMKT:CRMD) Will Use Its Cash Wisely

Jan 04
We're Hopeful That CorMedix (NYSEMKT:CRMD) Will Use Its Cash Wisely

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Joe Todisco en comparación con los beneficios de CorMedix?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

-US$46m

Jun 30 2024n/an/a

-US$53m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$2mUS$617k

-US$46m

Sep 30 2023n/an/a

-US$40m

Jun 30 2023n/an/a

-US$37m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$3mUS$378k

-US$30m

Compensación vs. Mercado: La compensación total ($USD2.46M) de Joe está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD3.21M).

Compensación vs. Ingresos: La compensación de Joe ha sido consistente con los resultados de la empresa en el último año.


CEO

Joe Todisco (48 yo)

2.5yrs

Permanencia

US$2,459,432

Compensación

Mr. Joseph Todisco, also known as Joe, MBA, serves as Chief Executive Officer of CorMedix Inc. since May 10, 2022. He has served as Director of CorMedix Inc. since March 18, 2022 and served as its Independ...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Joseph Todisco
CEO & Director2.5yrsUS$2.46m0.30%
$ 2.1m
Matthew David
Executive VP & CFO4.5yrsUS$1.03m0.017%
$ 118.5k
Erin Mistry
Executive VP & Chief Commercial Officer4.7yrsUS$1.26m0.021%
$ 147.7k
Elizabeth Masson-Hurlburt
Executive VP and Chief Clinical Strategy & Operations Officerless than a yearUS$844.81k0.013%
$ 89.6k
Kaufman Zelnick
Executive VPless than a yearsin datossin datos
Donna Ucci
Senior VP & Head of Global Quality2.5yrssin datossin datos
Tushar Mukherjee
Senior VP & Head of Technical Operations1.8yrssin datossin datos

2.5yrs

Permanencia media

47yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CRMD se considera experimentado (2.5 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Joseph Todisco
CEO & Director2.7yrsUS$2.46m0.30%
$ 2.1m
Myron Kaplan
Independent Chairman of the Board8.6yrsUS$191.96k0.30%
$ 2.1m
Alan Dunton
Independent Director5.7yrsUS$141.42k0.025%
$ 173.1k
Janet Dillione
Independent Director9.3yrsUS$147.42k0.088%
$ 606.9k
Steven Lefkowitz
Independent Director7.4yrsUS$162.42k0.13%
$ 879.6k
Gregory Duncan
Independent Director4yrsUS$141.42k0%
$ 0
Bruce Polsky
Member of Scientific Advisor Boardno datasin datossin datos
Saravanan Balamuthusamy
Member of Scientific Advisory Board2.6yrssin datossin datos
Sara Bonnes
Member of Scientific Advisory Board2.6yrssin datossin datos
Aru Narendran
Member of Scientific Advisory Board2.6yrssin datossin datos
Hannah Newman
Member of Scientific Advisory Board2.6yrssin datossin datos
Jonathan Waitman
Member of Scientific Advisory Board2.6yrssin datossin datos

2.7yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de CRMD no se considera experimentada (2.7 años de permanencia promedio), lo que sugiere una nueva junta directiva.